111, Inc. ADR
111, Inc. ADR is a healthcare and pharmaceutical platform focused on connecting consumers, pharmacies, and healthcare providers in China. The company operates through online retail pharmacy, Internet hospital, and B2B drug distribution businesses, supporting both individual customers and corporate partners with access to medical and wellness products, consultation services, and prescription-related offerings. Its platform combines digital and offline channels to serve the broader healthcare supply chain, with activities centered on pharmaceutical sales, patient services, and pharmacy network enablement. 111, Inc. ADR plays a role in China’s evolving digital healthcare market by helping streamline access to medicines and related services across consumer and business segments. Founded in 2010 and headquartered in Shanghai, the company is positioned as a technology-enabled participant in healthcare distribution and services.
$2.86
-$0.21 (-6.84%)
EOD Oct 23, 2026
The business is unprofitable at the operating level (-0.20% margin). The case rests on reaching sustained profitability.
Revenue declined 12.8% in the fiscal year ended Dec 2025.
Free cash flow declined 54% in the fiscal year ended Dec 2025 versus the year before, cash generation momentum has weakened. Negative free cash flow of -¥90M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥11.39B
▼ -12.8% YoY
Net Income (TTM)
-¥42M
▼ -8.4% YoY
Op. Margin
-0.20%
ROIC
-0.34%
▼ -0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-¥90M
▼ -53.7% YoY
Op. Cash Flow (TTM)
-¥90M
▼ -50.2% YoY
Net Debt
-¥324M
Net Cash Position
Cash & Equiv.
¥561M
3Y CAGR: -2.4%
Continue Research
Is 111, Inc. ADR (YI) overvalued?
111, Inc. ADR (YI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, 111, Inc. ADR scores 34/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is 111, Inc. ADR a high-quality business?+
111, Inc. ADR scores 34 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -0.2% operating margin and a -0.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is 111, Inc. ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh YI's valuation and scores 34/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Distribution
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing YI
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.